Takeda Submits NDA in Japan for Trelagliptin SuccinateBy
Takeda Pharmaceutical Company Limited has submitted a new drug application to the Japanese Ministry of Health, Labor and Welfare for trelagliptin succinate, a treatment for Type 2 diabetes.
Trelagliptin succinate, discovered by Takeda California, Inc., Takeda’s wholly-owned subsidiary located in San Diego, California, is a onceweekly dipeptidyl peptidase-IV (DPP-4) inhibitor. It controls blood glucose levels by selectively and continually inhibiting DPP-4, an enzyme that causes the inactivation of glucagon-like peptide-1 and glucagon-dependent insulinotropic polypeptide, incretin hormones that play an important role in blood glucose regulation. The inhibition of DPP-4 increases insulin secretion depending on blood glucose concentration, thereby controlling blood glucose levels.